Neuromyelitis optica spectrum disorder: do patients positive and negative for anti¿aquaporin-4 antibodies present distinct entities? A Colombian perspective P.A. Ortiz Salas; M. Gaviria Carrillo; G.A. Cortés Bernal; K. Moreno Medina; L.F. Roa; J.H. Rodríguez Quintana;

Should tocilizumab be the first line treatment for neuromyelitis optica together with rituximab? R. Sawaya; G. Saab; H. Moussa;

Functional outcomes of patients with NORSE and FIRES treated with immunotherapy: A systematic review P. Cabezudo-García; N. Mena-Vázquez; N.L. Ciano-Petersen; B. Oliver-Martos; P.J. Serrano-Castro;